Table 1. Clinical characteristics, laboratory findings, treatment, and outcome of patients with CMV colitis during dasatinib treatment.

[Ref]/ Patient	Age/Sex	Hematologic disease	Dasatinib duration		Lymphocyte	Coinfection pathogen	Serum CMV DNA titer (copies/ml)	Dasatinib during treatment	Treatment	Dasatinib after antiviral treatment	Relapse
[8]	F/39	CML, CP	30 month		Not mentioned	None	Not mentioned	Stop	Ganciclovir for 6 weeks	Restart	None
1	M/67	CML, CP	14 month		1,744/mm3	None	760	Stop	Ganciclovir for 19 days	Restart	None
2	F/43	CML, CP	2 month		1,115/mm3	Clostridium difficile	1,650	Stop	Ganciclovir for 12 days	Restart	None
3	M/51	CML, CP	14 month	1st episode	4,928/mm3	None	unchecked	Continued	None	Continued	Relapsed after 6 weeks
				2nd episode	4,190/mm3	None	unchecked	Continued	Valganciclovir for 21 day	Continued	None
4	M/54	Ph (+) ALL	3 month	1st episode	300/mm3	None	unchecked	Continued	None	Continued	relapsed after 2 weeks
				2nd episode	1,398/mm3	Clostridium difficile	925	Stop	Ganciclovir for 19 days	Restart	None
5	F/55	Ph (+) ALL	5 month		251/mm3	None	2500	Continued	Ganciclovir for 10 days	Stop	None

CMV, cytomegalovirus; F, female; CML, chronic myeloid leukemia; CP, chronic phase; M, male; Ph (+) ALL, Philadelphia chromosome-positive acute lymphoblastic leukemia.

Case of reference 9 was not included in the table because only abstract written in English was available.